Triglyceride-Glucose Index in Diabetic Nephropathy in Type 2diaberes Mellitus Patients
1 other identifier
observational
100
0 countries
N/A
Brief Summary
The aim of the present study is to investigate the associations between the TyG index and diabetic nephropathy in patients with type2 DM .
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2022
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 28, 2022
CompletedStudy Start
First participant enrolled
November 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2022
CompletedFirst Posted
Study publicly available on registry
November 2, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2023
CompletedNovember 2, 2022
October 1, 2022
Same day
October 28, 2022
October 28, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
TyG index in type 2diaberes Mellitus
Detecting the association between the TyG index and diabetic nephropathy in type 2 diabetes
Baseline
Eligibility Criteria
There will be no risk for the patients during the study Confidentiality will be assured. The participants will be informed about the research and they will hsve the right to refuse to participate. Written consents will be obtained from all the participants; illiterate participants will give their consent by fingerprints.
You may qualify if:
- patients with type 2 DM
You may not qualify if:
- \- (1) Individuals with obstructive uropathy, severe heart failure, stroke, liver disease, cancer, autoimmune disease (2) Pregnant woman. (3)End stage renal disease patients on dialysis ( glomerular filtration rate \<15 mL/min/1.73 m2) or renal transplantation.
- (4) Type 1 Diabetic patient. (5) Albuminuria due to non-diabetic renal disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (5)
Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88-98. doi: 10.1038/nrendo.2017.151. Epub 2017 Dec 8.
PMID: 29219149BACKGROUNDBeckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002 May 15;287(19):2570-81. doi: 10.1001/jama.287.19.2570.
PMID: 12020339BACKGROUNDYamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11(18):2279-99. doi: 10.2174/1381612054367300.
PMID: 16022668BACKGROUNDLiang S, Cai GY, Chen XM. Clinical and pathological factors associated with progression of diabetic nephropathy. Nephrology (Carlton). 2017 Dec;22 Suppl 4:14-19. doi: 10.1111/nep.13182.
PMID: 29155497BACKGROUNDLee MY, Hsiao PJ, Huang JC, Hsu WH, Chen SC, Chang JM, Shin SJ. ASSOCIATIONS BETWEEN TRIGLYCERIDE/HIGH-DENSITY LIPOPROTEIN CHOLESTEROL RATIO AND MICRO- AND MACROANGIOPATHIES IN TYPE 2 DIABETES MELLITUS. Endocr Pract. 2018 Jul;24(7):615-621. doi: 10.4158/EP-2017-0254.
PMID: 30048164BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Doctor
Study Record Dates
First Submitted
October 28, 2022
First Posted
November 2, 2022
Study Start
November 1, 2022
Primary Completion
November 1, 2022
Study Completion
October 1, 2023
Last Updated
November 2, 2022
Record last verified: 2022-10